LONDON, June 18, 2019 /PRNewswire/ -- The global human microbiome therapeutics market is estimated to grow at a CAGR of 60.2% in the first half of the forecast period. The global human microbiome therapeutics market is estimated to reach $1bn in 2024.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 250-page report you will receive 106 tables and 47 figures– all unavailable elsewhere.
The Visiongain report provides clear detailed insight into the global human microbiome therapeutics market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
To request sample pages from this report please contact Sara Peerun at email@example.com or refer to our website: https://www.visiongain.com/report/global-human-microbiome-therapeutics-market-forecast-2019-2029/#download_sampe_div
• Global Human Microbiome Therapeutics Market forecast from 2019-2029
• Global Human Microbiome Therapeutics Market revenue forecast 2019-2029 by Sector:
• Gastrointestinal Disorders
• Infectious Diseases
• Metabolic Diseases
• Dermatological Conditions
• Other Disorders
• Global Human Microbiome Therapeutics Market revenue forecast 2019-2029 by Region:
• EU5: Germany, France, U.K., Italy, Spain
• Rest of the World
The human microbiome market revenue forecast 2019-2029 for the US, EU5 and Japan markets are further broken down by sector.
• This report discusses the top 20 companies in the human microbiome therapeutics market:
• 4D Pharma
• AOBiome Therapeutics
• C3J Therapeutics
• Caelus Health
• Enterome Bioscience
• Ferring Pharmaceuticals
• Finch Therapeutics/Crestovo
• IGEN BIOTECH GROUP
• Intrexon Corporation
• MaaT Pharma
• MatriSys Biosystem
• Microbiome Therapeutics LLC
• Ritter Pharmaceuticals
• Second Genome
• Seres Therapeutics
• Synthetic Biologics
• Vedanta Biosciences
This report discusses collaborations and acquisition, recent developments, drugs developments and key pipeline products
• This report lists and discusses the main pipeline products in these main sectors: gastrointestinal disorders submarket, metabolic disorders submarket, infectious diseases submarket, dermatological disorders submarket and other disorders submarket.
• Qualitative analysis of the human microbiome therapeutics market in the form of a SWOT Analysis.
• Key Questions Answered by this Report:
• How is the market for human microbiome therapeutics evolving?
• What is driving and restraining the human microbiome therapeutics market dynamics?
• What are the market shares of the submarkets for gastrointestinal disorders, infectious diseases, metabolic diseases, dermatological conditions, and other disorders from the overall human microbiome therapeutics market?
• How will each of the submarket segments within the human microbiome therapeutics market grow over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each of the submarkets within the human microbiome therapeutics market develop from 2019 to 2029?
• Which submarkets will be the main driver of growth in the overall market from 2019 to 2029?
• How will the regional market shares in the human microbiome therapeutics market change by 2029 and which geographical region will lead the market in 2029?
To request a report overview of this report please contact Sara Peerun at firstname.lastname@example.org or refer to our website: https://www.visiongain.com/report/global-human-microbiome-therapeutics-market-forecast-2019-2029/
Did you know that we also offer a report add-on service? Email email@example.com to discuss any customized research needs you may have.
Companies covered in the report include:
4D Pharma Cork Limited
4D Pharma Leon
Aju IB Investment
Ally Bridge Group
Arctic Aurora Life Science
Aspire Capital Fund
Biological & Popular Culture, Inc.
Blue Turtle Bio
Cd4 Biosciences, Inc.
Cedars-Sinai Medical Centre
Chengdu Sen Nuo Wei Biotechnology Co., Ltd
Codexis Laboratories Hungary Kft
CRS Bio, Inc
Effective Pharmaceuticals, Inc.
Epitope Pharmaceuticals, Inc.
Finch Therapeutics Group, Inc.
Genten Therapeutics, Inc.
Global Bioscience Company
GT Biologics Limited
Harvest Capital Strategies, LLC
Igen Biotech Group
Intrexon Actobiotics N.V.
Intrexon Crop Protection
Intrexon Energy Partners II, LLC
Intrexon Energy Partners, LLC
Intrexon T1D Partners
Johnson & Johnson
Kolu Pohaku Management, LLC
Kolu Pohaku Technologies
MaaT Pharma SA
Merck & Co., Inc.
Microbiome Therapeutics, LLC
Nestle Health Science
NuMe Health LLC
Okanagan Specialty Fruits Inc.
OptiBiotix Health plc
OrbiMed HealthCare Fund Management
Pfizer Venture Investments
Pipex Therapeutics, Inc
Prev AbR LLC
Putney Drug Corp
Ritter Natural Sciences, LLC
Roche Venture Fund
Rock Springs Capital
S & I Ophthalmic
SR One Venture Partners
Synthetic Biologics, Inc.
Synthetic Biomics Inc.
Synthetic Genomics, Inc.
Tech Coast Angels (TCA)
The Microbiota Company Limited
Trans Ova Genetics LC
Tucana Health Limited
Vedanta Biosciences Inc.
Vertex Pharmaceuticals Inc.
List of Organizations Mentioned in the Report
Alimentary Pharmabiotic Centre
American Academy of Dermatology
APC Microbiome Institute
Central Drugs Standard Control Organisation (CDSCO)
French National Institute for Agricultural Research
Hadasit Medical Research Services & Development Ltd
Hadassah Medical Center
Institut National de la Recherche Agronomique
John Theurer Cancer Center of Hackensack Meridian Health
King's College London
La Trobe University
Lawrence Berkeley National Laboratory
Leiden University Medical Center
Medicines Control Council (MCC)
Medical University of Graz
Memorial Sloan Kettering Cancer Center
Ministry of Health, Labour and Welfare (MHLW)
Medicines and Healthcare products Regulatory Agency (MHRA)
Microbiome Institute at University College Cork
Murdoch Children Research Institute
National Institute of Allergy and Infectious Diseases
NYU Langone Health
Orange Country Research Center
Pan American Health Organization (PAHO)
Roswell Park Comprehensive Cancer Center
Saudi Food and Drug Authority (SFDA)
St. Joseph's Hamilton
Stanford Cancer Institute
Therapeutic Goods Administration (TGA)
The Endocrine Society
The Parker Institute for Cancer Immunotherapy
University of British Columbia
University of California
University of Melbourne
University of Minnesota
University of Nebraska
University of Pennsylvania
University of South Alabama (USA) Mitchell Cancer Institute
University of Texas at Austin
University of Texas MD Anderson Cancer Center
University of Tokyo
USA Mitchell Cancer Center
World Health Organization (WHO)
World Intellectual Property Organization WIPO
World Trade Organization (WTO)
To see a report overview please e-mail Sara Peerun on firstname.lastname@example.org